Anavex Life Sciences Corp. Common Stock (AVXL) Stock
NASDAQ · AVXL
Key stats
- Market cap
- $98.26M
- Price / Earnings ratio
- -8.0x
- EPS (TTM)
- -$0.15
- Volume
- Loading
- 52-week high
- $7.25
- 52-week low
- $1.07
Source: third-party data provider, as of November 13, 2026
Compare with AVXL
Recent news

Business Wire
Robbins LLP Urges AVXL Stockholders Who Lost Money Investing in Anavex Life Sciences Corp. to Contact the Firm for Information About Leading the Class Action
NeutralAVXLOctober 22, 2026
Business WireNeutral
Robbins LLP Urges AVXL Stockholders Who Lost Money Investing in Anavex Life Sciences Corp. to Contact the Firm for Information About Leading the Class Action
AVXL

Business Wire
AVXL Investors: Anavex Life Sciences Corp. Shares Declined By $0.19 On August 31, 2026 – Contact Kirby McInerney LLP to Discuss Your Rights
NeutralAVXLOctober 14, 2026
Business WireNeutral
AVXL Investors: Anavex Life Sciences Corp. Shares Declined By $0.19 On August 31, 2026 – Contact Kirby McInerney LLP to Discuss Your Rights
AVXL

Business Wire
Deadline Alert: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
NeutralAVXLOctober 8, 2026
Business WireNeutral
Deadline Alert: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
AVXL

Business Wire
Deadline Soon: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
NeutralAVXLOctober 6, 2026
Business WireNeutral
Deadline Soon: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
AVXL
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 29.15
- MACD 12/26/9
- -0.19
- EMA 9 of MACD
- -0.22
- MACD histogram
- 0.03
- SMA 50
- $1.83
- Price below SMA 50
- EMA 50
- $1.73
- Price below EMA 50
- SMA 200
- $2.93
- Price below SMA 200
- EMA 200
- $2.83
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
194M128M64M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-46.4M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Business Wire
Robbins LLP Urges AVXL Stockholders Who Lost Money Investing in Anavex Life Sciences Corp. to Contact the Firm for Information About Leading the Class Action
NeutralAVXLOctober 22, 2026
Business WireNeutral
Robbins LLP Urges AVXL Stockholders Who Lost Money Investing in Anavex Life Sciences Corp. to Contact the Firm for Information About Leading the Class Action
AVXL

Business Wire
AVXL Investors: Anavex Life Sciences Corp. Shares Declined By $0.19 On August 31, 2026 – Contact Kirby McInerney LLP to Discuss Your Rights
NeutralAVXLOctober 14, 2026
Business WireNeutral
AVXL Investors: Anavex Life Sciences Corp. Shares Declined By $0.19 On August 31, 2026 – Contact Kirby McInerney LLP to Discuss Your Rights
AVXL

Business Wire
Deadline Alert: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
NeutralAVXLOctober 8, 2026
Business WireNeutral
Deadline Alert: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
AVXL

Business Wire
Deadline Soon: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
NeutralAVXLOctober 6, 2026
Business WireNeutral
Deadline Soon: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
AVXL

Business Wire
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
NeutralAVXLOctober 5, 2026
Business WireNeutral
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
AVXL

Business Wire
Law Offices of Howard G. Smith Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
NeutralAVXLOctober 5, 2026
Business WireNeutral
Law Offices of Howard G. Smith Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
AVXL

Business Wire
Law Offices of Frank R. Cruz Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
NeutralAVXLOctober 1, 2026
Business WireNeutral
Law Offices of Frank R. Cruz Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
AVXL

Business Wire
Securities Fraud Investigation Into Anavex Life Sciences Corp. (AVXL) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
NeutralAVXLOctober 1, 2026
Business WireNeutral
Securities Fraud Investigation Into Anavex Life Sciences Corp. (AVXL) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
AVXL

Business Wire
Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
NeutralAVXLOctober 1, 2026
Business WireNeutral
Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
AVXL

Business Wire
Securities Class Action Filed Against Anavex Life Sciences Corp. – AVXL Investors Encouraged to Contact Kirby McInerney LLP
NeutralAVXLSeptember 30, 2026
Business WireNeutral
Securities Class Action Filed Against Anavex Life Sciences Corp. – AVXL Investors Encouraged to Contact Kirby McInerney LLP
AVXL
News tone: automated (AI) classification of the article's content, not a price prediction.
About Anavex Life Sciences Corp. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees34
CEODr. Terrie Kellmeyer Ph.D.
IPO DateAug 2, 2006
HeadquartersNew York, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Terrie Kellmeyer Ph.D. | Interim Chief Executive Officer | — |
| Ms. Sandra Boenisch C.P.A., CGA | Principal Financial Officer & Treasurer | 1981 |
Fundamentals
Valuation
Price-to-book value0.93
PEG ratio0.00
Profitability
Return on Equity-11.00%
Return on Assets-11.00%
EBITDA$-13.00M
Trading
Average volume1,162,893
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 29.15
- MACD 12/26/9
- -0.19
- EMA 9 of MACD
- -0.22
- MACD histogram
- 0.03
- SMA 50
- $1.83
- Price below SMA 50
- EMA 50
- $1.73
- Price below EMA 50
- SMA 200
- $2.93
- Price below SMA 200
- EMA 200
- $2.83
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -9.8 | -3.2 | ||||||||||
| 2022 | -26.1 | -0.7 | +16.9 | -32.0 | +0.7 | +21.5 | -0.4 | -2.9 | +6.9 | +16.0 | -28.9 | +4.4 |
| 2023 | +12.3 | -13.4 | -11.5 | -4.3 | +12.4 | -10.7 | +3.0 | -3.1 | -17.5 | -12.3 | +28.3 | +23.0 |
| 2024 | -1.3 | -16.4 | -3.6 | -27.3 | +10.0 | +5.0 | +65.5 | -8.5 | +4.0 | +21.7 | +38.3 | +15.2 |
| 2025 | -23.7 | -8.4 | +3.7 | +18.5 | -19.1 | +22.0 | +21.1 | -13.9 | -6.1 | -11.5 | -50.5 | -6.8 |
| 2026 | +27.7 | -2.0 | -32.2 | +7.7 | -8.7 | -13.1 | +6.6 | -5.1 | -29.6 | -37.0 | -0.9 |
Compare stocks
Market cap
$98.26M
-
-
-
Price / Earnings ratio
-8.00
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,162,893
-
-
-
Earnings per share
$-0.15
-
-
-



